Skip to main content

Table 3 Pfcrt genotypes among subclinical and clinical isolates from three regions of Myanmar 2008-2009

From: Molecular surveillance for drug-resistant Plasmodium falciparum in clinical and subclinical populations from three border regions of Burma/Myanmar: cross-sectional data and a systematic review of resistance studies

  No. (%)  
  Resistanta WT K76 OR (95% CI)a
Karen State (n = 58) 58 (100) 0 (0.0)  
Clinic 27 (100) 0 (0.0)  
Screening 31 (100) 0 (0.0) n/a
Kachin State (n = 46) 43 (93.5) 3 (6.5)  
Clinic 12 (100) 0 (0)  
Screening 31 (91.2) 3 (8.8) n/a
Chin-Mizoram (n = 186) 178 (95.7) 8 (4.3)  
Clinic 88 (93.6) 6 (6.4)  
Screening 90 (97.8) 2 (2.2) 0.3 (0.1-1.7)
Screening vs clinic Total b (n = 232) 221 (95.3) 11 (4.7)  
Clinic 100 (94.3) 6 (5.6)  
Screening 121 (96.0) 5 (4.0) 0.7 (0.2-2.2)
Anti-malarial treatment Total c (n = 232) 221 (95.3) 11 (4.7)  
No treatment in past 8 weeks 174 (95.6) 8 (4.4)  
Treatment in past 8 weeks 47 (94.0) 3 (6.0) 1.4 (0.4-5.0)
  1. aResistant genotypes: 259 amplified K76T; n = 20 isolates that failed to amplify either K76T or wild type K76 were assumed to harbour a resistant genotype (eg SVMNT). Dropping these 20 observations from the analysis does not qualitatively modify the results.
  2. bStandard errors corrected for clustering within village cluster (n = 13).
  3. cTotals exclude Karen State given apparent fixation (100%) of the K76T allele.
  4. Percentages may not sum to 100 due to rounding.